Lizard Venom Regrows 'Irreplaceable' Cartilage

Brad Stanfield

Apr 27, 2026

Episode description

🩺 Get your personalized health plan: https://drstanfield.com

💊 Supplements I Take: https://drstanfield.com/pages/my-supplements

💊MicroVitamin+ (Pro) Powder: https://drstanfield.com/products/microvitamin-plus
💊MicroVitamin Standard Capsules: https://drstanfield.com/products/microvitamin

✔️ X: https://x.com/BradStanfieldMD
✔️ Patreon: https://www.patreon.com/bradstanfieldmd

Here are the links to the research papers referenced in the video:
Exenatide history (Eng's mail-order venom) — https://peptideinitiative.com/peptide-chronicles/exenatide
Gila monster feeding pattern — https://www.zmescience.com/ecology/animals-ecology/gila-monster-ozempic-origin/
Raufman NIH "fishing expedition" — https://whyy.org/segments/ozempic-how-gila-monster-venom-led-to-weight-loss-drugs/
Exenatide / Wikipedia (Yalow training, exendin-4 isolation, VA patent refusal, 3 years rejection, Holst quote, Amylin licensing) — https://en.wikipedia.org/wiki/Exenatide
Exendin-4 53% similarity to GLP-1 — https://pubmed.ncbi.nlm.nih.gov/15866711/
Native GLP-1 short half-life — https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2024.1431292/full
VA "veteran-specific ailment" — https://www.diabetesincontrol.com/dr-john-engs-research-found-that-the-saliva-of-the-gila-monster-contains-a-hormone-that-treats-diabetes-better-than-any-other-medicine/
Byetta FDA approval / dosing — https://investor.lilly.com/news-releases/news-release-details/amylin-and-lilly-announce-fda-approval-byettatm-exenatide
Exenatide modest weight loss — https://pmc.ncbi.nlm.nih.gov/articles/PMC3241299/
Liraglutide / Victoza approval — https://www.nejm.org/doi/full/10.1056/NEJMp1001578
Ozempic FDA approval — https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-of-ozempic-semaglutide-injection-for-the-treatment-of-adults-with-type-2-diabetes-300567052.html
Semaglutide 14.9% weight loss — https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
Wegovy obesity approval (2021) — https://www.prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-for-wegovy-to-treat-adults-with-obesity-based-on-unprecedented-efficacy-for-a-prescription-medicine-in-clinical-trials-301306246.html
SELECT cardiovascular trial — https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
Harvard Gazette (Josephine Li & Nils Kruger quotes) — https://news.harvard.edu/gazette/story/2026/02/whats-next-for-glp-1s/
GLP-1 substance use disorders — https://www.bmj.com/content/392/bmj-2025-086886
Hardaway "less rewarding" quote — https://www.uab.edu/news/research-innovation/the-glp-1-revolution-what-uab-researchers-are-discovering-about-how-these-drugs-work
FLOW kidney trial — https://www.nejm.org/doi/full/10.1056/NEJMoa2403347
GLP-1R wide tissue distribution — https://pmc.ncbi.nlm.nih.gov/articles/PMC9455625/
Hunter 1743 cartilage declaration — https://royalsocietypublishing.org/rstl/article/42/470/514/25806/VI-Of-the-structure-and-diseases-of-articu-lating
Cartilage limited self-repair — https://pmc.ncbi.nlm.nih.gov/articles/PMC10071204/
Cartilage repair unmet needs — https://www.mdpi.com/1648-9144/61/1/24
595 million OA prevalence — https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(23)00163-7/fulltext
Knee replacement cost ($19,568 US) — https://pmc.ncbi.nlm.nih.gov/articles/PMC10368258/
Karin Payne "no cure" quote — https://news.cuanschutz.edu/medicine/arthritis-glp-1-agonists-obese-patient
Weight loss → 4x knee-joint load reduction — https://pubmed.ncbi.nlm.nih.gov/15986358/
STEP 9 trial (semaglutide + knee OA) — https://www.nejm.org/doi/abs/10.1056/NEJMoa2403664
Qin et al. — pair-fed mouse design, mechanism, human pilot, 17% cartilage increase, WOMAC, authors' caution — https://www.cell.com/cell-metabolism/fulltext/S1550-4131(26)00008-2
Di Chen "independent of weight loss" quote — https://news.cgtn.com/news/2026-02-12/-Weight-loss-wonder-drug-can-also-treats-osteoarthritis-study-finds-1KHcUiXzHsQ/p.html

Thumbnail by James Kelly
Video edited by Troy Young
Script by John Milliken

The links above are affiliate links, so I receive a small commission every time you use them to purchase a product. The content contained in this video, and its accompanying description, is not intended to replace viewers’ relationships with their own medical practitioner. Always speak with your doctor regarding the content of this channel, and especially before using any products, services, or devices discussed on this channel.

Mindsip insights from this episode:

Increase cartilage thickness with semaglutide treatment

A pilot clinical study on humans showed that the semaglutide group had an average 17% increase in cartilage thickness, suggesting regeneration.

Advocate for drug development despite initial rejection

The inventor, John Eng, paid for the initial patent out of his own pocket and spent three years trying to convince pharmaceutical companies to develop the drug, as the concept seemed absurd by industry standards.

#research

Challenge belief: cartilage repair independent of weight loss

A controlled experiment in mice demonstrated that semaglutide's protective effect on cartilage is independent of weight loss, challenging the traditional belief that improvement relies solely on weight reduction.

#regeneration

#semaglutide

Upgrade cartilage cell energy source for enhanced repair

Semaglutide appears to flip a switch inside cartilage cells, upgrading them to a more efficient energy source that produces enough power to start the repair process.

#regeneration

#semaglutide

Reduce brain's reward response to food and substances with GLP-1 medications

GLP-1 medications seem to reduce the brain's reward responses, making not only food but also alcohol, nicotine, and opioids less rewarding.

#addiction

#GLP1

Challenge belief on cartilage recovery with semaglutide research

New research on semaglutide challenges the long-held medical belief that cartilage, once destroyed, can never be recovered.

#regeneration

#semaglutide

Discover GLP-1 drug origins in Gila monster venom

The GLP-1 drug class originated from a compound called Exendin-4, discovered in Gila monster venom, which is 53% identical to the human hormone GLP-1 but lasts for hours instead of minutes.